Melanotan-2 vs PT-141

Melanotan-2

Melanotan 2 is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its cyclic structure confers enhanced metabolic stability and broad melanocortin receptor affinity, activating MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function and appetite), and MC5R (exocrine gland function). This multi-receptor activity profile distinguishes it from more selective melanocortin analogues and accounts for its diverse range of biological effects observed in research settings. Originally developed at the University of Arizona by Hruby and colleagues, Melanotan 2 was first characterized in studies published in the Journal of Medicinal Chemistry (1989), where its potent melanotropic activity was established. Subsequent research by Dorr et al. in Archives of Dermatological Research demonstrated dose-dependent increases in skin pigmentation without UV exposure. Studies in Neuroscience by Wessells et al. documented that MC4R activation by Melanotan 2 produced pro-erectile effects in animal models, findings that later informed the development of PT-141 (Bremelanotide), which was derived directly from Melanotan 2 as a more targeted therapeutic candidate. Compared to Melanotan 1 (Afamelanotide), which is linear and MC1R-selective, Melanotan 2's cyclic structure gives it broader receptor coverage and higher potency per mole. However, this reduced selectivity means research must account for concurrent effects across multiple melanocortin pathways. Both peptides share the Nle4/D-Phe7 substitutions that distinguish them from native alpha-MSH. Lyophilized Melanotan 2 should be stored at -20°C, protected from light. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. Researchers in dermatology, sexual medicine, neuropharmacology, and melanocortin receptor biology are the primary investigators of this compound.

PT-141

PT-141, also known as Bremelanotide, is a cyclic heptapeptide melanocortin receptor agonist derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) analogue Melanotan II. Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 operates centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus and limbic system, initiating downstream dopaminergic signaling pathways associated with arousal and sexual motivation. Phase III clinical trials conducted by Palatin Technologies and published in The Journal of Sexual Medicine demonstrated that PT-141 administration produced statistically significant increases in satisfying sexual events and desire scores in premenopausal women with hypoactive sexual desire disorder (HSDD). Research by Diamond et al. (2006) in the International Journal of Impotence Research showed efficacy in male subjects who had not responded to PDE5 inhibitor therapy, suggesting a fundamentally different mechanism of action. Additional preclinical studies have identified potential roles in hemorrhagic shock models, where MC receptor activation provided protective effects on organ perfusion. Compared to sildenafil (Viagra) and tadalafil (Cialis), which are peripherally acting vasodilators, PT-141 is unique in its central nervous system mechanism. This distinction is significant because it suggests PT-141 may address desire-based dysfunction rather than purely mechanical erectile function. Melanotan II, its parent compound, activates multiple MC receptors non-selectively, while PT-141 shows preferential MC4R and MC1R activity. Store lyophilized PT-141 at -20°C. Reconstitute with bacteriostatic water and keep at 2-8°C, using within 4 weeks. PT-141 is investigated by sexual medicine researchers, neuroendocrinologists, and emergency medicine scientists studying melanocortin-based interventions.

Frequently Asked Questions